Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Scrutiny Of EpiPen Pricing Invited By Mylan Lobbying, Congressman Says

Executive Summary

House Oversight Committee’s diatribe against Mylan has been fueled by the company’s efforts to engage lawmakers to advance its business interests, Rep. Mulvaney tells CEO Bresch: 'You asked for it.'

You may also be interested in...



Insulin Makers May Be First In Crosshairs Of DeGette Rx Pricing Investigation

Rep. Diana DeGette, new chair of US House Energy and Commerce Committee's Subcommittee on Oversight and Investigations, said insulin is a good example of problems with drug pricing and promised to call drug company CEOs to hearings.

Drug Pricing, Supply Chain Issues May Get House Hearing

Energy & Commerce Health Subcommittee is considering a hearing, but leadership may be concerned Democrats will use the session to air grievances over Republican efforts to repeal the Affordable Care Act.

The US Drug Pricing Hearing Pharma Wants

Senate hearing will examine drug delivery system, but industry still faces possibility of another public shaming about increasing drug costs.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS119178

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel